The Effective Role of Hydroxyapatite Based Composites in Anticancer Drug Delivery Systems.
Tumors consist of a heterogeneous population of cancer cells carrying multiple genetic mutations. During the past few decades, efforts have focused on curing cancer using various methods. However, traditional cancer therapies still carry some drawbacks, such as limited application for only a few cancer types, killing of normal cells, poor specificity, and associated toxicity. To overcome these disadvantages, drug-delivery methods that emphasize biomaterials have been developed and applied to optimize cancer treatments. Hydroxyapatite (HAP) is a biocompatible inorganic material that can be applied in biomedical drug-delivery applications. This review discusses the features and properties of HAP that make it an effective biomaterial and provides a comprehensive summary of recent studies in which HAP and composites containing HAP were applied as anticancer drug carriers. We believe that HAP-based composites show great promise for cancer treatment using controlled release of therapeutic agents, leading to enhanced efficiency, selective release of drugs, and prohibition of cancer cell proliferation.
Department of Chemistry, Eastern Mediterranean University, Gazimagusa, TRNC via Mersin 10, Turkey.
Samaneh
S
Saber-Samandari
Department of Nanotechnology and Advanced Materials, Materials and Energy Research Center, Alborz, Iran.
Nader
N
Nezafati
New Technologies Research Centre, Amirkabir University of Technology, Tehran, Iran.
Saeed
S
Saber-Samandari
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001672:Biocompatible Materials / Q000737:chemistry*; D003692:Delayed-Action Preparations / Q000737:chemistry; D004337:Drug Carriers / Q000737:chemistry*; D006801:Humans; D006882:Hydroxyapatites / Q000737:chemistry*; D009369:Neoplasms / Q000188:drug therapy*; D010316:Particle Size; D013499:Surface Properties
D000970:Antineoplastic Agents; D001672:Biocompatible Materials; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D006882:Hydroxyapatites